RxDoctor Payments DataLook up a doctor →

Jeffrey Dodson, MD

Dermatology · Bridgeport, WVNPI 1649212903

Payments from drug & device makers

$9,997in general payments, 2019–2025

Across 517 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Journey Medical Corporation$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$764
  • Lilly USA, LLC$681
  • E.r. Squibb & Sons, L.L.C.$540
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$1,00010%
  • Food & beverage$8,70587%
  • Education$2933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,997 in reported general payments places this provider in the 80th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$346,756
Medicare patients
1,122
Services billed
6,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$350,407
Skyrizi PenRisankizumab-Rzaa13$276,806
OtezlaApremilast38$193,692
Cosentyx Unoready PenSecukinumab19$128,590
Enbrel SureclickEtanercept12$92,186
Dupixent SyringeDupilumab14$61,809
Tacrolimus34$8,617
Fluorouracil125$7,874
Mometasone Furoate190$4,250
Triamcinolone Acetonide355$4,088
Ketoconazole139$2,750
Clobetasol Propionate50$2,613
Doxycycline Hyclate119$2,432
Betamethasone Dipropionate28$2,203
Betamethasone Valerate61$1,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$86$193,69238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 39 dermatology providers in West Virginia.

Other dermatology in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →